

# Hamid Bassiri

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/733374/publications.pdf>

Version: 2024-02-01

67  
papers

2,993  
citations

218592

26  
h-index

175177

52  
g-index

76  
all docs

76  
docs citations

76  
times ranked

4468  
citing authors

#	ARTICLE	IF	CITATIONS
1	American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 3. <i>Arthritis and Rheumatology</i> , 2022, 74, .	2.9	146
2	IL-1 receptor antagonist, MIS-C, and the peculiar autoimmunity of SARS-CoV-2. <i>Lancet Rheumatology</i> , The, 2022, 4, e305-e307.	2.2	2
3	TH-MYCN tumors, but not tumor-derived cell lines, are adrenergic lineage, GD2+, and responsive to anti-GD2 antibody therapy. <i>Oncolmunology</i> , 2022, 11, .	2.1	6
4	Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T19. <i>Clinical Cancer Research</i> , 2022, 28, 3804-3813.	3.2	17
5	Human Adenovirus 7-Associated Hemophagocytic Lymphohistiocytosis-like Illness: Clinical and Virological Characteristics in a Cluster of Five Pediatric Cases. <i>Clinical Infectious Diseases</i> , 2021, 73, e1532-e1538.	2.9	12
6	Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) Antibody Responses in Children With Multisystem Inflammatory Syndrome in Children (MIS-C) and Mild and Severe Coronavirus Disease 2019 (COVID-19). <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021, 10, 669-673.	0.6	45
7	American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 2. <i>Arthritis and Rheumatology</i> , 2021, 73, e13-e29.	2.9	314
8	Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma. <i>Nature Communications</i> , 2021, 12, 511.	5.8	85
9	Cutaneous Findings in SARS-CoV-2-Associated Multisystem Inflammatory Disease in Children. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab074.	0.4	10
10	Combined use of emapalumab and ruxolitinib in a patient with refractory hemophagocytic lymphohistiocytosis was safe and effective. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29026.	0.8	11
11	Deep immune profiling of MIS-C demonstrates marked but transient immune activation compared with adult and pediatric COVID-19. <i>Science Immunology</i> , 2021, 6, .	5.6	152
12	Diagnostic Challenges in Pediatric Hemophagocytic Lymphohistiocytosis. <i>Journal of Clinical Immunology</i> , 2021, 41, 1213-1218.	2.0	10
13	Reply. <i>Arthritis and Rheumatology</i> , 2021, 73, 1342-1343.	2.9	0
14	Distinct Bioenergetic Features of Human Invariant Natural Killer T Cells Enable Retained Functions in Nutrient-Deprived States. <i>Frontiers in Immunology</i> , 2021, 12, 700374.	2.2	3
15	Skewed Cytokine Responses Rather Than the Magnitude of the Cytokine Storm May Drive Cardiac Dysfunction in Multisystem Inflammatory Syndrome in Children. <i>Journal of the American Heart Association</i> , 2021, 10, e021428.	1.6	18
16	Comprehensive Secretome Profiling Elucidates Novel Disease Biology and Identifies Pre-Infusion Candidate Biomarkers to Predict the Development of Severe Cytokine Release Syndrome in Pediatric Patients Receiving CART19. <i>Blood</i> , 2021, 138, 167-167.	0.6	1
17	The Role of PF4 Antibodies in Pediatric Sars-Cov-2 Infections. <i>Blood</i> , 2021, 138, 1004-1004.	0.6	0
18	Proteomic profiling of MIS-C patients indicates heterogeneity relating to interferon gamma dysregulation and vascular endothelial dysfunction. <i>Nature Communications</i> , 2021, 12, 7222.	5.8	41

#	ARTICLE	IF	CITATIONS
19	American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 1. Arthritis and Rheumatology, 2020, 72, 1791-1805.	2.9	323
20	Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children. Blood Advances, 2020, 4, 5174-5183.	2.5	30
21	Convalescent plasma for pediatric patients with SARS-CoV-2-associated acute respiratory distress syndrome. Pediatric Blood and Cancer, 2020, 67, e28693.	0.8	37
22	Multidisciplinary Guidance Regarding the Use of Immunomodulatory Therapies for Acute Coronavirus Disease 2019 in Pediatric Patients. Journal of the Pediatric Infectious Diseases Society, 2020, 9, 716-737.	0.6	40
23	Evidence of thrombotic microangiopathy in children with SARS-CoV-2 across the spectrum of clinical presentations. Blood Advances, 2020, 4, 6051-6063.	2.5	105
24	Distinguishing Multisystem Inflammatory Syndrome in Children From Kawasaki Disease and Benign Inflammatory Illnesses in the SARS-CoV-2 Pandemic. Pediatric Emergency Care, 2020, 36, 554-558.	0.5	20
25	Enhancing Neuroblastoma Immunotherapies by Engaging iNKT and NK Cells. Frontiers in Immunology, 2020, 11, 873.	2.2	20
26	Multisystem Inflammatory Syndrome in Children During the Coronavirus 2019 Pandemic: A Case Series. Journal of the Pediatric Infectious Diseases Society, 2020, 9, 393-398.	0.6	317
27	Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS-CoV-2. Journal of Clinical Investigation, 2020, 130, 5967-5975.	3.9	319
28	Convalescent Plasma for COVID-19: An Old Therapy for a Novel Pathogen. , 2020, 17, .		2
29	Evidence of Microangiopathy in Children with Sars-Cov-2 Regardless of Clinical Presentation. Blood, 2020, 136, 28-29.	0.6	0
30	3502 Stimulating iNKT Cell-Mediated Neuroblastoma Cytotoxicity in a Mouse Model. Journal of Clinical and Translational Science, 2019, 3, 21-21.	0.3	0
31	Intravenous colistin use for infections due to MDR Gram-negative bacilli in critically ill paediatric patients: a systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy, 2019, 74, 2497-2506.	1.3	8
32	Genetics of Primary Hemophagocytic Lymphohistiocytosis. , 2019, , 83-111.		0
33	Cutting Edge: Murine NK Cells Degranulate and Retain Cytotoxic Function without Store-Operated Calcium Entry. Journal of Immunology, 2017, 199, 1973-1978.	0.4	10
34	Emerging Infections and Pertinent Infections Related to Travel for Patients with Primary Immunodeficiencies. Journal of Clinical Immunology, 2017, 37, 650-692.	2.0	6
35	Abstract 1630: Modulation of the neuroblastoma microenvironment via polyamine blockade. , 2017, , .		0
36	Invariant natural killer T cells in hematopoietic stem cell transplantation: killer choice for natural suppression. Bone Marrow Transplantation, 2016, 51, 629-637.	1.3	16

#	ARTICLE	IF	CITATIONS
37	Antitumor Responses of Invariant Natural Killer T Cells. <i>Journal of Immunology Research</i> , 2015, 2015, 1-10.	0.9	26
38	Translational development of difluoromethylornithine (DFMO) for the treatment of neuroblastoma. <i>Translational Pediatrics</i> , 2015, 4, 226-38.	0.5	63
39	Abstract B203: Polyamine blockade modulates the neuroblastoma microenvironment. , 2015, , .		0
40	iNKT Cell Cytotoxic Responses Control T-Lymphoma Growth <i>In Vitro</i> and <i>In Vivo</i> . <i>Cancer Immunology Research</i> , 2014, 2, 59-69.	1.6	60
41	Older Mice Intranasally Sensitized with <i>Aspergillus Fumigatus</i> Develop Stronger Eosinophilic Esophageal Inflammation Compared to Their Younger Counterparts. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, AB257.	1.5	0
42	Epitope Spreading Is Required for Long-Term Protection Against Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 3717-3717.	0.6	0
43	Invariant NKT cells. <i>Oncolmmunology</i> , 2013, 2, e27440.	2.1	20
44	The adaptor molecule SAP plays essential roles during invariant NKT cell cytotoxicity and lytic synapse formation. <i>Blood</i> , 2013, 121, 3386-3395.	0.6	28
45	Murine natural killer immunoreceptors use distinct proximal signaling complexes to direct cell function. <i>Blood</i> , 2013, 121, 3135-3146.	0.6	32
46	X-linked lymphoproliferative disease (XLP). <i>Atlas of Genetics and Cytogenetics in Oncology and Haematology</i> , 2012, , .	0.1	0
47	The Adaptor Molecule Signaling Lymphocytic Activation Molecule-Associated Protein (SAP) Regulates IFN- $\gamma$ and IL-4 Production in V $\beta$ 14 Transgenic NKT Cells via Effects on GATA-3 and T-bet Expression. <i>Journal of Immunology</i> , 2009, 182, 1370-1378.	0.4	22
48	It's up to you Egr2. <i>Immunology and Cell Biology</i> , 2009, 87, 361-363.	1.0	2
49	X-linked lymphoproliferative disease (XLP): a model of impaired anti-viral, anti-tumor and humoral immune responses. <i>Immunologic Research</i> , 2008, 42, 145-159.	1.3	29
50	Differential Requirement for the SAP-Fyn Interaction during NK T Cell Development and Function. <i>Journal of Immunology</i> , 2008, 181, 2311-2320.	0.4	46
51	A Requirement for IL-2/IL-2 Receptor Signaling in Intrathymic Negative Selection. <i>Journal of Immunology</i> , 2001, 166, 5945-5954.	0.4	46
52	Thymic Stromal-Cell Abnormalities and Dysregulated T-Cell Development in IL-2-Deficient Mice. <i>Autoimmunity</i> , 1998, 5, 287-302.	0.6	16
53	Lymphoid hyperplasia, autoimmunity, and compromised intestinal intraepithelial lymphocyte development in colitis-free gnotobiotic IL-2-deficient mice. <i>Journal of Immunology</i> , 1998, 160, 385-94.	0.4	132
54	Involvement of the Fas/Fas ligand pathway in activation-induced cell death of mycobacteria-reactive human gamma delta T cells: a mechanism for the loss of gamma delta T cells in patients with pulmonary tuberculosis. <i>Journal of Immunology</i> , 1998, 161, 1558-67.	0.4	77

#	ARTICLE	IF	CITATIONS
55	B7 blockade prevents activation-induced cell death of thymocytes. <i>International Immunology</i> , 1997, 9, 1663-1668.	1.8	7
56	Delayed allograft rejection by T cell receptor V $\beta$ 28.1 transgenic mice peripherally tolerized to Mls-1. <i>European Journal of Immunology</i> , 1994, 24, 1710-1713.	1.6	8
57	Genetically engineered grafts to study xenommunity: a role for indirect antigen presentation in the destruction of major histocompatibility complex antigen deficient xenografts. <i>Surgery</i> , 1994, 116, 242-8; discussion 248-9.	1.0	4
58	Prolonged survival of class I deficient mouse islet allografts but not xenografts. <i>Transplantation Proceedings</i> , 1994, 26, 748.	0.3	2
59	Allograft Rejection by T Cell Receptor Transgenic Mice. <i>Journal of Surgical Research</i> , 1993, 54, 437-444.	0.8	11
60	DELETION OF DONOR-REACTIVE T LYMPHOCYTES IN ADULT MICE AFTER INTRATHYMIC INOCULATION WITH LYMPHOID CELLS. <i>Transplantation</i> , 1993, 55, 871-876.	0.5	39
61	ISLET ALLOGRAFT, ISLET XENOGRAFT, AND SKIN ALLOGRAFT SURVIVAL IN CD8. <i>Transplantation</i> , 1993, 55, 718-721.	0.5	37
62	Donor antigen-specific T-lymphocyte deletion after intrathymic inoculation. <i>Transplantation Proceedings</i> , 1993, 25, 305-6.	0.3	4
63	Pancreatic islet allograft and xenograft survival in CD8+ T-lymphocyte-deficient recipients. <i>Transplantation Proceedings</i> , 1993, 25, 961-2.	0.3	14
64	INDEFINITE SURVIVAL OF MHC CLASS I-DEFICIENT MURINE PANCREATIC ISLET ALLOGRAFTS. <i>Transplantation</i> , 1992, 54, 1085-1089.	0.5	79
65	Direct assessment of the role of NK cells in autoimmune diabetes. <i>Journal of Surgical Research</i> , 1992, 52, 601-604.	0.8	8
66	MAJOR-HISTOCOMPATIBILITY-COMPLEX RESTRICTED AND NONRESTRICTED AUTOIMMUNE EFFECTOR MECHANISMS IN BB RATS. <i>Transplantation</i> , 1991, 52, 662-667.	0.5	8
67	The contribution of MHC antigen modulation to islet allograft rejection. <i>Hormone and Metabolic Research Supplement Series</i> , 1990, 25, 104-8.	0.2	2